Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy

Annals of Oncology

Volumn 21, Issue 12, 2010, Pages 2356-2360

  Renard, F ^a   Vankrunkelsven, P ^b   van Eycken, L ^a   Henau, K ^a   Boniol, M ^c,d   Autier, P ^c,d  

^a Belgian Cancer Registry   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d INTERNATIONAL PREVENTION RESEARCH INSTITUTE   (France)

Author keywords

Attributable fraction; Belgium; Breast cancer; Hormone replacement therapy

Indexed keywords

ESTROGEN; GESTAGEN; TIBOLONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ATTRIBUTABLE RISK; BELGIUM; BREAST CANCER; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; DRUG WITHDRAWAL; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT WITHDRAWAL; TUMOR VOLUME;

EID: 78649482867     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq240     Document Type: Article

References (22)

1. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288(3): 321-333.
2. Chlebowski RT, Hendrix SL, Langer RD et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003; 289(24): 3243-3253.
3. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362(9382): 419-427.
4. Cogliano V, Grosse Y, Baan R et al. Carcinogenicity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol 2005; 6(8): 552-553.
5. Curado M, Edwards B, Shin H et al. Cancer Incidence in Five Continents. IARC Scientific Publication No. 160. Lyon, France: IARC 2007.
6. Ferlay J, Autier P, Boniol M et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18(3): 581-592.
7. Ferlay J, Bray F, Pisani P, Parkin M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France: IARC Press 2004.
8. Vankrunkelsven P, Kellen E, Lousbergh D et al. Reduction in hormone replacement therapy use and declining breast cancer incidence in the Belgian province of Limburg. Breast Cancer Res Treat 2009; 118(2): 425-432.
9. Waterhouse J, Muir C, Correa P et al. Cancer Incidence in Five Continents. Vol. III. IARC Scientific Publication No. 15. Lyon, France: IARC Scientifics Publications 1976.
10. IMS Health Belgium RdC61B. Drug Sales in Belgium per Three Months. Brussels: Belgium. 2009.
11. Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108(6): 1354-1360.
12. IFEB. Register Sales of Reimbursed Drugs per Province. 2009; http://www.ifeb.be (July 2009, date last accessed).
13. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum 1953; 9(3): 531-541.
14. Bray F, McCarron P, Parkin DM. The changing global patterns of female breast cancer incidence and mortality. Breast Cancer Res 2004; 6(6): 229-239.
15. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997; 350(9084): 1047-1059.
16. Holli K, Isola J, Cuzick J. Hormone replacement therapy and biological aggressiveness of breast cancer. Lancet 1997; 350(9092): 1704-1705.
17. Glass AG, Lacey JV Jr., Carreon JD, Hoover RN. Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status. J Natl Cancer Inst 2007; 99(15): 1152-1161.
18. Katalinic A, Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 2008; 107(3): 427-430.
19. Bouchardy C, Morabia A, Verkooijen HM et al. Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer 2006; 6: 78.
20. Jemal A, Ward E, Thun MJ. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 2007; 9(3): R28.
21. Fabri V, Remacle A, Mertens R. Programme de dépistage du cancer du sein. 4. Intermutualistic Agency, Brussels 2007.
22. Ravdin PM, Cronin KA, Howlader N et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 2007; 356(16): 1670-1674.